This educational programme focuses on putative mechanistic links between epilepsy and cardiovascular disease, raises clinically relevant questions about anti-epileptic drug use in the context of cardiac disease, and addresses unresolved issues of practical importance in this area of “neuro-cardiology”.
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.